#Taletrectinib
LightNews LightNews
oncodaily.bsky.social
Taletrectinib (Ibtrozi): What Patients Should Know in 2025?

oncodaily.com/drugs/taletr...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Taletrectinib #Ibtrozi #NSCLC #LungCancer #TargetedTherapy
Taletrectinib (Ibtrozi): What Patients Should Know About in 2025? - OncoDaily
Learn more about Taletrectinib (Ibtrozi), its uses in cancer, side effects and their management, dosage, and what patients should expect.
oncodaily.com
July 11, 2025 at 8:46 PM
oncodaily.bsky.social
FDA approval of Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer
@fda.gov

oncodaily.com/opinion/311850

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #FDA #Taletrectinib #ROS1
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
FDA approves taletrectinib for ROS1-positive NSCLC. TRUST-I/II trials show high systemic & intracranial responses in advanced NSCLC.
oncodaily.com
June 15, 2025 at 7:13 PM
oncodaily.bsky.social
Taletrectinib (Ibtrozi) 2025 Updates: Uses in Cancer, Side effects, Dosage, Expectations, and more

oncodaily.com/drugs/taletr...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Taletrectinib #Ibtrozi #NSCLC #TargetTherapy
Taletrectinib (Ibtrozi) 2025 Updates: Uses in Cancer, Side effects, Dosage, Expectations and more - OncoDaily
Taletrectinib (Ibtrozi) is target therapy for ROS1 mutated NSCLC. Learn about its uses, side effects, dosage, what to expect during treatment.
oncodaily.com
July 10, 2025 at 6:38 PM
onclive.bsky.social
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials @stephenvliu.bsky.social @mskcancercenter.bsky.social @nufeinbergmed.bsky.social @harvardmed.bsky.social @ucsdhealth.bsky.social #lcsm www.onclive.com/view/taletre...
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.
www.onclive.com
December 17, 2024 at 3:08 PM
jameabraham.bsky.social
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... @n8pennell.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social
April 5, 2025 at 7:20 PM
tnewsomdavis.bsky.social
Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC

👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs

💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data

#ELCC25
March 27, 2025 at 3:55 PM
scinews.bsky.social
U.S. FDA Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1+ NSCLC

"If approved, taletrectinib represents a potential best-in-class treatment option for patients with advanced ROS1+ NSCLC"

www.businesswire.com/news/home/20...
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S
https://www.businesswire.com/news/home/20241223905597/en/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Nuvation-Bio’s-New-Drug-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer
December 27, 2024 at 12:51 AM
drdavidmcmahon.bsky.social
ascopubs.org/doi/10.1200/...

very impressive efficacy and safety (manageable TRK-specific AEs) data for taletrectinib in ROS1+ NSCLC.
ORR 88 and 56% (1L/2+L).
61% in the G2032R common resistance mutation.
76% intracranial response.
mPFS 44.6m in the untreated population 👏
Taletrectinib in <i>ROS1</i>+ Non–Small Cell Lung Cancer: TRUST
PURPOSETaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies...
ascopubs.org
April 6, 2025 at 8:56 AM
247qualitymeds.bsky.social
Buy Ibtrozi (enquire about price, availability and access in India) - 247qualitymeds.com/product/tale...
Buy Taletrectinib 200 mg Capusles Online in India at Best Price
Buy Ibtrozi (taletrectinib) capsules in India through trusted import support. Call 24/7 QualityMeds at +91 9967979080 for pricing and availability updates.
247qualitymeds.com
September 22, 2026 at 11:11 AM
iaslc.bsky.social
A new ROS1+ NSCLC therapy is here.
In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care.

🎧 Tune in here: bit.ly/FDATaletrect...

#IASLC #NSCLC
FDA Approval: Taletrectinib and ROS1 NSCLC | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for ...
bit.ly
June 26, 2025 at 2:22 PM
oncoalert.bsky.social
The FDA has approved taletrectinib for adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) — including those who have previously received ROS1 TKIs. A major advance for a rare molecular subtype of lung cancer. 🧵

🔗 www.fda.gov/drugs/resour...
June 11, 2025 at 6:16 PM
onclive.bsky.social
Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ #NSCLC #oncology

www.onclive.com/view/taletre...
Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC
China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.
www.onclive.com
January 3, 2025 at 4:40 PM
onco404.bsky.social
🎯 Taletrectinib shines in TRUST-I/II trials, offering new hope for ROS1+ NSCLC patients! 🚀

@ascocancer.bsky.social

🔬 Key Findings 👇

#Onco404 #Cancer #Oncology #MedSky #OncSky #LungCancer #PrecisionMedicine #ClinicalTrials #NSCLC #JCO #ASCO
April 5, 2025 at 2:55 PM
cancertherapyadv.bsky.social
Taletrectinib improves outcomes compared to crizotinib in TKI-naive patients with ROS1-positive NSCLC, according to research presented at #ELCC25 by Dr. Misako Nagasaka of the University of California Irvine School of Medicine. #ELCC2025 #lcsm
March 27, 2025 at 4:20 PM
onclive.bsky.social
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC #lcsm #oncology www.onclive.com/view/nccn-gu...
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC
The NCCN Clinical Practice Guidelines in Oncology for NSCLC recommend taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC.
www.onclive.com
June 25, 2025 at 3:40 PM
oncodaily.bsky.social
Long-Term Outcomes With Taletrectinib In ROS1 NSCLC - Stephen Liu

@stephenvliu.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Stephen V Liu: Long-Term Outcomes With Taletrectinib In ROS1 NSCLC - OncoDaily
Stephen V Liu: Long-Term Outcomes With Taletrectinib In ROS1 NSCLC / Caicun Zhou, cancer, Feiwu Ran, Huijie Fan, Journal of Clinical Oncology, Lung Cance,
oncodaily.com
April 28, 2026 at 1:32 PM
cancertherapyadv.bsky.social
Taletrectinib can be effective in both TKI-naïve and TKI-pretreated advanced #NSCLC, according to a recent pooled analysis. #lcsm shorturl.at/uZwLK
Taletrectinib Provides “Prolonged Disease Control” in ROS1+ NSCLC
Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” accordin...
shorturl.at
April 15, 2025 at 2:05 PM
onclive.bsky.social
📣 The FDA has accepted an sNDA for taletrectinib in advanced ROS1-positive NSCLC, supported by updated TRUST-I/II data showing ~90% ORR, durable responses, and strong CNS activity 🧠📊
⏳ PDUFA date set for January 2027
Read more ➡️ www.onclive.com/view/fda-acc...
#LungCancer #NSCLC #ROS1 #Oncology
FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC | OncLive
An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC
www.onclive.com
May 6, 2026 at 5:58 PM
medicine.stitches.today
Taletrectinib offers high response rates and extended survival in cancer patients, demonstrating strong efficacy and manageable safety profiles.

by Pérol M, Li W (...) Zhou C et 16 al. in J Clin Oncol #MedSky

👉 get more here

📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00275
April 12, 2025 at 4:34 AM
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Taletrectinib for ROS1+ Advanced NSCLC #lcsm #oncology

Read more here🔗: onclive.com/view/fda-app...
June 11, 2025 at 5:05 PM
medicine.stitches.today
Taletrectinib demonstrated high effectiveness and manageable safety in treating ROS1-positive patients, especially those naïve to prior therapy.

by Pérol M, Li W (...) Zhou C et 16 al. in J Clin Oncol #MedSky

👉 get more here

📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00275
June 10, 2025 at 4:41 PM
cancertherapyadv.bsky.social
Updated findings from TRUST-I & TRUST-II were presented in a poster at #WCLC26 🫁

Taletrectinib has shown durable ORRs & a manageable safety profile in patients with ROS1-positive #NSCLC, regardless of ROS1 fusion partners or prior chemo exposure.

Read: https://bit.ly/4y0b18h
September 17, 2026 at 3:09 PM
247qualitymeds.bsky.social
Taletrectinib Price and the Journey to Accessing Ibtrozi in India
Learn more: 247qualitymeds.mystrikingly.com/blog/taletre...
Taletrectinib Price and the Journey to Accessing Ibtrozi in India
The cost of Taletrectinib is only one part of the equation when sourcing Ibtrozi for treatment in India.
247qualitymeds.mystrikingly.com
August 20, 2026 at 11:49 AM
l2plabs.bsky.social
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroups NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today...
dlvr.it
August 4, 2026 at 12:02 PM